Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...

Comirnaty's annual revenue was roughly $40 billion in 2022 and 2023 and over $10 billion in 2023 (BioNTech books half of Pfizer's gross profits, profit share from other smaller partners ...

Regarding the 2024-2025 Pfizer-BioNTech COVID-19 vaccine ... The lawmaker has served in the Senate since 2011 and was most ...

British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK patent rights in messenger RNA technology with its blockbuster COVID-19 ...

Both Moderna and Pfizer-BioNTech manufacture the COVID vaccine in lower doses ... A Kaiser Family Foundation survey from 2022 ...

Antiviral Immunoglobulin Market. The global antiviral immunoglobulin market was valued at USD 4.6 billion in 2022 and is ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer and BioNTech ... during the coming 2022/23 flu season in the northern hemisphere.

In the US, Pfizer and BioNTech filed a lawsuit against CureVac in July 2022, seeking confirmation that Comirnaty does not infringe three CureVac patents, and the latter has since filed a ...